Posts Tagged ‘Celgene’

RIMM Rocks, Palm Rolls

9:10am (EST) Futures are pointing towards a higher open this morning following yesterday’s selloff.  The Dow ended Thursday with a 132 point drop and settled at 10,308 while the S&P 500 fell 13 and finished at 1,096. Today is a quadruple witching day which means contracts for stock index futures,Read more

More

Dendreon Holding Steady/ Close April Calls

8:45am (EST) Dendreon (DNDN, $6.37, down $0.21) has held above $6 all week after hitting a high of $7.35 on Monday despite numerous “sell” recommendations on the stock. This has killed all of the momentum as talking heads continue to talk negative about the move the stock has made. ByRead more

More

Tuesday's Tidbits

9:00 am (EST) I had a busy day on Monday with everything going on but I wanted to update some of the positions we have open and what is happening with them. The Celgene (CELG, $42.31, up $0.16) April 40 calls (LGHDH, $3.00, up $0.25) had a stop of $2.25-$2.50Read more

More

Weekly Wrap for 4/5/09

Friday Morning Notes

We got the curve ball on Monday, today we got the wildcard. The market is headed for a lower open after the horrendous unemployment report we got this morning. The U.S. unemployment rate jumped to 8.5% in March – the highest in 25 years. The good news is we shouldRead more

More

Amazon.com Surging/ Celgene Right Behind

11:30 pm (EST) Amazon.com (AMZN, $76.00, up $2.50) continues its march higher despite another downgrade this morning. Barclays Capital lowered its rating from “Overweight” to “Equal-weight” with a $70 price target. They went on to say that Amazon has outperformed the market by 60% since December. And? The stock alsoRead more

More

Celgene Update

1:30pm (right coast time) Celgene (CELG, $37.94, down $6.46) dipped below $37 which pushed the April 40 calls (LGHDH, $1.05, down $4.35) to a low of 75 cents. They were at $1.20 when I mentioned them this morning and I said they could go as low as 80 cents. IfRead more

More

Celgene Gets Whacked

Celgene (CELG, $38.30, down $6.10) is down 14% this morning after offering a disappointing outlook on earnings to Wall Street. The company said first-quarter and 2009 earnings and revenue would miss expectations due to weaker sales of its drug Thalomid. This is no April Fool’s joke, bubba. For those ofRead more

More

Market at 12-Year Lows, What Next?

The Dow fell over 4% Monday and you could tell by the opening bell that we were headed much lower. Once 7,000 failed, the Dow found some support at 6,800 and that was the battle line going into the closing bell. The big number with the S&P is 700 andRead more

More

Celgene Heads Lower

Celgene (CELG, $42.05, down $2.68) was the only thing that looked good this morning for a trade when the market looked poised to open lower. I listed a bunch of call options in case we got a rebound this morning but you could tell in last night’s Weekly Wrap theRead more

More

CFTC Disclosure:

GOVERNMENT REGULATIONS REQUIRE DISCLOSURE OF THE FACT THAT WHILE THESE METHODS MAY HAVE WORKED IN THE PAST, PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE PERFORMANCE. WHILE THERE IS A POTENTIAL FOR PROFITS THERE IS ALSO A RISK OF LOSS. A LOSS INCURRED IN CONNECTION WITH Momentum Options Trading, LLC CAN BE SIGNIFICANT. YOU SHOULD THEREFORE CAREFULLY CONSIDER WHETHER TRADING IS SUITABLE FOR YOU IN LIGHT OF YOUR FINANCIAL CIRCUMSTANCE. THERE IS SUBSTANTIAL RISK IN TRADING. A LOSS INCURRED IN CONNECTION WITH FUTURES TRADING CAN BE SIGNIFICANT. WE MAKE NO CLAIM REGARDING PAST OR FUTURE PERFORMANCE. WE MERELY TRACK EVERY TRADE AND SHOW THE PERFORMANCE OF ALL TRADES THE SYSTEM OR NEWSLETTER PRODUCES. SIMULATED TRADING IS DIFFERENT THAN TRADING REAL MONEY. HYPOTHETICAL RESULTS ARE NOT REAL RESULTS. PLEASE CONTACT YOUR BROKER ABOUT THE RISK OR TRADING STOCKS, OPTIONS OR FUTURES. ALL COMMUNICATIONS ARE OPINIONS NOT ADVICE.

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.